Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- 12 Downloads
Purpose of Review
The US Food and Drug Administration issued a recall of textured breast implants in July 2019 secondary to their association with anaplastic large cell lymphoma. This brief review serves to summarize what is actually known about breast implant associated anaplastic large cell lymphoma.
Since the FDA’s first preliminary report in 2011, there have been a reported worldwide total of 573 breast implant associated anaplastic large cell lymphoma (BIA-ALCL) cases, including 33 deaths. In addition to halting the implantation of textured implants, the July recall served to increase awareness and vigilance when caring for patients with a history of textured breast implants. Recommendations continue to be against voluntary implant removal.
In the setting of the FDA recall, the importance of comprehensive counseling remains paramount. For patients with textured breast implants, it is vital to ensure patient awareness with thorough education on warning signs and the importance of follow-up.
KeywordsBreast implant-associated lymphoma Textured breast implants Current guidelines Pathogenesis Diagnosis Treatment
Compliance with Ethics Guidelines
Conflict of Interest
The authors declare that they have no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.•• The FDA takes action to protect patients from risk of certain textured breast implants; requests allergan voluntarily recall certain breast implants and tissue expanders from the market: FDA safety communication. FDA. 2019. https://www.fda.gov/medical-devices/safety-communications/fda-takes-action-protect-patients-risk-certain-textured-breast-implants-requests-allergan. Accessed August 5, 2019 2019. The August 2019 FDA recall of textured breast implants due to the link with anaplastic large cell lymphoma.
- 2.Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S, et al. Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. J Clin Oncol. 2016;34(2):160–8. https://doi.org/10.1200/JCO.2015.63.3412.CrossRefPubMedGoogle Scholar
- 3.2018 Plastic Surgery Statistics Report. 2018.Google Scholar
- 5.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for T-cell lymphomas. Version 2.2019 ed. December 17, 2018.Google Scholar
- 6.•• Clemens MW, Brody GS, Mahabir RC, Miranda RN. How to diagnose and treat breast implant-associated anaplastic large cell lymphoma. Plast Reconstr Surg. 2018;141(4):586e–99e. https://doi.org/10.1097/PRS.0000000000004262A review of the diagnostic criteria, appropriate work-up modalities, and lines of therapy for patients with BIA-ALCL. CrossRefPubMedGoogle Scholar
- 7.•• McCarthy CM, Loyo-Berrios N, Qureshi AA, Mullen E, Gordillo G, Pusic AL, et al. Patient registry and outcomes for breast implants and anaplastic large cell lymphoma etiology and epidemiology (PROFILE): initial report of findings, 2012-2018. Plast Reconstr Surg. 2019;143(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma):65S–73S. https://doi.org/10.1097/PRS.0000000000005571A review of the PROFILE Registry data, with emphasis on how the creation of the database has served to strengthen our understanding of BIA-ALCL. CrossRefPubMedGoogle Scholar
- 8.Hu H, Jacombs A, Vickery K, Merten SL, Pennington DG, Deva AK. Chronic biofilm infection in breast implants is associated with an increased T-cell lymphocytic infiltrate: implications for breast implant-associated lymphoma. Plast Reconstr Surg. 2015;135(2):319–29. https://doi.org/10.1097/PRS.0000000000000886.CrossRefPubMedGoogle Scholar
- 10.•• Collett DJ, Rakhorst H, Lennox P, Magnusson M, Cooter R, Deva AK. Current risk estimate of breast implant-associated anaplastic large cell lymphoma in textured breast implants. Plast Reconstr Surg. 2019;143(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma):30S–40S. https://doi.org/10.1097/PRS.0000000000005567A retrospective review of global epidemiologic data and current literature outlining the incidence, risk, and prevalence of BIA-ALCL. CrossRefPubMedGoogle Scholar
- 11.• Magnusson M, Beath K, Cooter R, Locke M, Prince HM, Elder E, et al. The epidemiology of breast implant-associated anaplastic large cell lymphoma in Australia and New Zealand confirms the highest risk for grade 4 surface breast implants. Plast Reconstr Surg. 2019;143(5):1285–92. https://doi.org/10.1097/PRS.0000000000005500A retrospective review of BIA-ALCL cases in Australia and New Zealand, with the confirmed cases supporting a link between textured breast implants and anaplastic large cell lymphoma. CrossRefPubMedGoogle Scholar
- 12.•• Clemens MW, Jacobsen ED, Horwitz SM. 2019 NCCN consensus guidelines on the diagnosis and treatment of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Aesthet Surg J. 2019;39:S3–S13. https://doi.org/10.1093/asj/sjy331A review of the NCCN consensus guidelines regarding standardization of BIA-ALCL treatment. CrossRefPubMedGoogle Scholar